Events


The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP)
Nov
22
to 23 Nov

The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP)

Join the APIS team at ABP x BDIAP 2024

The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP) will be holding a joint meeting this year on Friday 22 November and Saturday 23 November 2024 at the Royal Society of Medicine, 1 Wimpole Street, London.

Come and meet the APIS team to discover the:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 qPCR Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA qPCR Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

  • The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.

  • The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.

Use this link to contact us and schedule a meeting.


View Event →
APIS goes to AMP 2024!
Nov
19
to 23 Nov

APIS goes to AMP 2024!

Come and meet the APIS team to discover the:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 qPCR Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA qPCR Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

  • The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.

  • The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.

Use this link to contact us and schedule a meeting.

Don’t miss our poster sessions on:

  1. Highly Sensitive ESR1 Mutation Detection with the APIS Kit:  Performance and LoD Testing in Varied Wildtype Backgrounds

    Session: Solid Tumors                     

    Date: Friday, November 22nd

    Time: 9:15am – 10:15am Pacific

  2. Implementing Semi-quantitative Methods for Breast Cancer Biomarker Assessment Using the APIS Breast Cancer Subtyping Kit        

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

  3. Advancing HER2 Stratification: Evaluating the APIS Breast Cancer Subtyping Kit Against IHC/ISH for Precise HER2 Quantification

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

  4. Validating the APIS Breast Cancer Subtyping Kit: mRNA Expression of ER, PR, HER2 and Ki67 Compared to Immunohistochemistry in 374 Breast Cancer Core Needle Biopsies

    Session: Solid Tumors                     

    Date: Saturday, November 23rd

    Time: 9:15am – 10:15am Pacific

View Event →
International Annual Meeting on Breakthroughs in breast cancer research and treatment
Oct
21
to 22 Oct

International Annual Meeting on Breakthroughs in breast cancer research and treatment

BBC Annual Meeting 2024

Come and meet the APIS team to discover the:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

  • The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.

  • The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.

Use this link to contact us and schedule a meeting.

View Event →
8th World Congress on Controversies in Breast Cancer
Sept
11
to 13 Sept

8th World Congress on Controversies in Breast Cancer

Don’t miss the APIS team at the 8th World Congress on Controversies in Breast Cancer

Come and meet the APIS team at booth #7 to discover the:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

Use this link to contact us and schedule a meeting.

View Event →
European Congress of Pathology 2024
Sept
7
to 11 Sept

European Congress of Pathology 2024

The APIS team are excited to be exhibiting at the European Congress of Pathology!

Come and meet us at booth #120 to learn about:
·       APIS Breast Cancer Subtyping Kit

·       APIS ESR1 Mutations Kit

·       APIS PIK3CA Mutations Kit

·       APIS MET Alterations Kit

& our new PGx Assays!

Don’t miss our poster sessions on:

1. Assessment of the dynamic range and quantitative potential of ER, PR, HER2 and Ki67 gene expression by RT-qPCR

Session: Poster Session Breast Pathology and Best Poster Sessions

Date: 08/09/2024

Time: 09:30 - 10:30 and 16:45 - 17:15

2. Measuring ESR1 mutations in liquid biopsy and FFPE breast tissue using qPCR  

Session: Poster Session Breast Pathology

Date: 08/09/2024

Time: 09:30 - 10:30

Poster number: 015

3. Assessment of RNA quality following extraction from FFPE using various protocols compatible with the APIS Breast Cancer Subtyping Kit

Session: Poster Session Breast Pathology

Date: 08/09/2024

Time: 09:30 - 10:30

Poster number: 013

4. Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC/ISH for Accurate HER2 Quantification

No poster session - available as PDF.

Use this link to contact us and schedule a meeting.

We look forward to seeing you in Florence!

View Event →
From Data to Insights: Interactive Visualisation for Target Discovery
Jul
18

From Data to Insights: Interactive Visualisation for Target Discovery

Join us for an educational webinar session as we delve into the fascinating world of interactive visualisations to interpret complex data generated in target validation process with APIS Target Triage pipeline.  

Novak Martinovic from APIS Assay Technologies will share his expertise and insights into this challenging field. 

Webinar Highlights: 

  • Enhancing Complex Data Interpretation: 
    Learn how to make sense of complex data sets using interactive visualisations. Discover techniques that help you gain more accurate and insightful results. 

  • Practical Demonstrations: 
    Watch real-world examples of powerful visualisation tools in action. See how these methods are used specifically to aid in finding targets during drug discovery. 

  • Integration Strategies: 
    Get essential tips and best practices for incorporating interactive visualisations into your research workflow. Improve your efficiency and effectiveness in discovering drug targets. 

Don’t miss the opportunity to gain practical knowledge and network with fellow experts in the field.

Register now 👉🚀https://attendee.gotowebinar.com/register/6603149406283876960?source=APIS+Website

Want to learn more? Book a meeting with us to discuss 👉https://bit.ly/ApisBioinformatics

View Event →
Understanding HER2 Expression in Breast Cancer: The Emerging Role of HER2-Low
Jun
26

Understanding HER2 Expression in Breast Cancer: The Emerging Role of HER2-Low

Join us for an educational webinar session where we explore the relevance of HER2 expression in invasive breast cancer.

Our presenters, Anna Gasior and Leanne Gough from APIS Assay Technologies, will provide a comprehensive overview of the latest advancements in HER2 expression testing, with a particular emphasis on the emerging concept of HER2-low. 

Webinar Highlights: 

  • HER2 as a predictive and prognostic marker in invasive breast cancer 

  • HER2 testing methodologies 

  • The significance of HER2-low classification 

  • Implications for treatment strategies  

Have your questions answered by experts in gene mutation assay development and validation!

Register here: https://attendee.gotowebinar.com/register/3150349743017902679?source=APIS+Website

View Event →
APIS goes to Sheffield Pathology 2024
Jun
18
to 20 Jun

APIS goes to Sheffield Pathology 2024

Don’t miss the APIS team at Sheffield Pathology 2024!

Come and chat to us and discuss:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

Use this link to contact us and schedule a meeting.

View Event →
APIS will be attending ESMO Breast Cancer 2024!
May
15
to 17 May

APIS will be attending ESMO Breast Cancer 2024!

Don’t miss the APIS team attending ESMO Breast at booth 27!

Come and chat to us to discuss:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

Use this link to contact us and schedule a meeting.

View Event →
Don't miss the APIS team at ABS conference 2024!
May
13
to 14 May

Don't miss the APIS team at ABS conference 2024!

APIS will be exhibiting at The Association of Breast Surgery 2024!

Don’t miss the team at booth 42 to discuss:

  • The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

  • The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

  • The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).

Use this link to contact us and schedule a meeting.

View Event →
APIS goes ECCMID 2024!
Apr
27
to 30 Apr

APIS goes ECCMID 2024!

Don’t miss APIS at ECCMID 27th April, 2024

Come and meet our team of expertise at booth F32

It’s a perfect chance to discuss:

·        Contract assay development opportunities

·        Clinical Compliance Services

·        Clickmers

·        Infectious disease and microbiology capabilities

Interested? Contact us to arrange a meeting: Contact — APIS Assay Technologies Ltd

View Event →
APIS goes to BioIT-World Conference & Expo
Apr
15
to 17 Apr

APIS goes to BioIT-World Conference & Expo

Heading to BioIT-World Conference in Boston 15-17 April?

So is our Head of Bioinformatics, Aleksandar Mihajlovic

It’s a perfect chance to discuss:

·        Opportunities in AI & ML for biomarker and drug discovery

·        Algorithm and bioinformatics pipeline development and evidence extrapolation from data

·        Bioinformatics cloud platforms development

Interested? Schedule a call with us via our booking link: https://bit.ly/ApisBioinformatics

View Event →
Streamlining Biomarker Discovery: From Theory to Application
Apr
11

Streamlining Biomarker Discovery: From Theory to Application

🌟 Webinar Alert! 🌟

Streamlining Biomarker Discovery: From Theory to Application

Join us for an educational webinar session as we delve into the fascinating world of biomarker discovery and its crucial role in Breast Cancer Subtyping. Our presenters Svetozar Nesić and Marko Tumbas from APIS Assay Technologies, will guide you through the complexities of this cutting-edge field.

🔍 Webinar Highlights:

  • Biomarker selection

  • Designing a biomarker signature

  • Develop a predictive algorithm capable of addressing the high dimensionality of biological datasets

  • Determine the minimal marker subset capable of achieving the desired predictive power

  • Translate findings obtained using data to train ML models and test obtained signature robustness

📅 Date: 11th April 2024  ⏰ Time: 14:00 (BST)

 

Don’t miss this opportunity to gain practical knowledge and network with fellow enthusiasts. Register now 🚀 https://attendee.gotowebinar.com/register/2901291665925058903?source=APIS+Website

Want to learn more? Book a meeting with us to discuss 👉 https://bit.ly/ApisBioinformatics

View Event →
ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance
Mar
20

ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance

Oestrogen receptor 1 (ER/ESR1) mutations have arisen as crucial biomarkers for endocrine therapy resistance in ER positive metastatic breast cancer. Detecting these mutations is key for understanding acquired resistance during treatment.

APIS will be joined by SensID GmbH to deliver this FREE educational webinar on ESR1 mutations and the importance of their accurate and sensitive detection.

Gain insights into:

- ESR1 mutations significance in breast cancer and their role in endocrine therapy resistance

- APIS ESR1 Mutations Kit, an accessible method to detect ESR1 mutations

- SensID ESR1 reference set to ensure accurate detection of mutations in cell-free DNA (cfDNA)

Have your questions answered by experts in gene mutation assay development and validation!

Register here: https://attendee.gotowebinar.com/register/8248345354064775003?source=APIS+Website

View Event →
Clickmers<span class="sqsrte-text-color--darkAccent">®</span> webinar
Feb
15

Clickmers® webinar

Join us for our educational webinar on ‘Clickmers® as a Powerful Tool in a Rapidly Changing Pathogen Landscape’.

Clickmers are versatile DNA-based detection molecules that can be used in various types of assays ranging from diagnostics to therapeutics.

Gain insights into:

  • The fundamentals of Clickmers, their role, and significance in therapeutics and diagnostics

  • How Clickmers unique properties enable faster responses to emerging pathogens

  • How Clickmers can differentiate between tick-borne encephalitis (TBEV) NS1 and other highly similar flavivirus NS1 protein

We hope you can join us on: Thursday 15th February, 14:00-15:00 (GMT)

Register to secure your spot: https://attendee.gotowebinar.com/register/6764377390145455196?source=APIS+LinkedIn


View Event →
BioX Webinar Ep.3
Dec
14

BioX Webinar Ep.3

Join us for the third episode of our educational webinars, this time on "Navigating the Future of Drug Discovery: Public Data & AI in Target Discovery"

During this session, Aleksandar Mihajlovic and Aleksandra Gulbicka (APIS Assay Technologies Ltd.) will guide you through the realm of drug discovery, exploring the synergistic integration of public data and AI.
 
Don’t miss gaining valuable insights into:
·       Setting the Stage for Innovation: Discover how the convergence of public data and AI is reshaping the landscape of pharmaceutical research
·       Modifying Questions for Biomarkers: Explore novel strategies for adapting biomarker-related questions in drug discovery research
·       Clickmers: Uncover the fundamentals of Clickmers, their role, and significance in modern drug discovery

We hope you can join us on: Thu 14th December, 14:00-15:00 (GMT)

Register to secure your spot 👉
https://bit.ly/3RboQfS


View Event →
Precision Oncology Europe
Nov
14
to 15 Nov

Precision Oncology Europe

Dont miss APIS presenting at Precision Oncology Europe - ‘Advantages of Using Clickmer Technology for the Detection of Biomarkers’

Dr. Nora Karnowski’s presentation will outline the advantages of Clickmer technology and how they can support biomarker development:

Clickmers are modified DNA aptamers that bind to their biomarker targets with nanomolar affinity. They can be developed within weeks, have high specificity and can be quantified using enzymatic, fluorescent, or qPCR readout for improved sensitivity.

The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.

The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.

Use this link to contact us and schedule a meeting.

View Event →
AMP 2023
Nov
14
to 18 Nov

AMP 2023

Join the APIS team at AMP 2023

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.

Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.

The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.

The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.

Use this link to contact us and schedule a meeting

View Event →
Decoding the Future: How Cloud Computing is Reshaping Bioinformatics
Oct
26

Decoding the Future: How Cloud Computing is Reshaping Bioinformatics

Join us for the second episode of our educational webinars on "Decoding the Future: How Cloud Computing is Reshaping Bioinformatics".

During this session, presenters Nikola Nonkovic (APIS Assay Technologies) and Victor Weigman (BioSkryb) will guide you through the transformative journey of bioinformatics from its inception in traditional data centers to the expansive possibilities within the cloud.

Webinar highlights:

  • The Evolution of Bioinformatics: Traverse the journey from data centers to the limitless potential of the cloud.

  • Cloud Technologies & Bioinformatics: Understand the profound impact of cloud solutions in the realm of bioinformatics, specifically as it applies to single-cell genomic and transcriptomic analysis.

  • To Build or Not to Build: Delve into the decision-making process behind creating custom bioinformatics applications versus licensed solutions.

We hope you can join us on: Thu 26th October, 15:00-16:00 (GMT)

Register to secure your spot:
https://bit.ly/3tkNSRw

View Event →
APIS are presenting at ACRO Biosystems Symposium
Oct
25

APIS are presenting at ACRO Biosystems Symposium

Don’t miss APIS presenting at ACRO Biosystems Symposium - ‘The potential of Clickmers to accelerate the development of safer drugs’

Dr. Nora Karnowski’s presentation will outline how the Clickmer technology can support drug development

  • Fast discovery, characterisation and assay development to aid e.g. patient stratification

  • Innovative selection methods to achieve special features such as targeting of undruggables like GPCRs or conditional activation

Register now 👉: https://bit.ly/3FmjusL

View Event →
BioTechX Europe Conference
Oct
4
to 6 Oct

BioTechX Europe Conference

Don’t miss the APIS team at BioTechX Europe!

APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.

Utilising the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data APIS directly addresses the historical failures of translating biomarkers into clinical utility.

Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.

Use this link to contact us and schedule a meeting.

View Event →
Nextflow Bioinformatics Pipelines and Workflow Management: A Comprehensive Webinar
Sept
19

Nextflow Bioinformatics Pipelines and Workflow Management: A Comprehensive Webinar

Join Srdjan Kasapovic and guest speaker Dr. Harshil Patel (Seqera Labs) for an informative webinar on "Nextflow Bioinformatics Pipelines and Workflow Management".

In this session, we will provide valuable insights into:

  • Nextflow bioinformatics pipelines

  • Pipeline design best practices

  • The difference between open source and commercial pipelines

  • Nextflow Tower for efficient workflow management

We hope you can join us on:

Tue 19th September, 16:00 PM - 17:00 PM (CEST)

Register here to secure your spot and have your questions answered by our expert presenters!

View Event →
35th European Congress of Pathology
Sept
9
to 13 Sept

35th European Congress of Pathology

Join the APIS team at the 35th European Congress of Pathology in Dublin, Ireland.

APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.

We proudly present:

The APIS Breast Cancer Subtyping Kit, a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.

The new APIS ESR1 Mutations Kit, an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.

Use this link to contact us and schedule a meeting.

View Event →
World Clinical Biomarker & CDx 2023
Sept
5
to 8 Sept

World Clinical Biomarker & CDx 2023

The APIS team will be exhibiting and presenting at the 13th World Clinical Biomarker & CDx 2023 in Boston.

Be sure not to miss Program Lead, Joanna Gorniak, PhD, presenting on Day 2, Friday 8th September at 4 PM with her talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.

APIS is leveraging the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data to directly address the historical failures of translating biomarkers into clinical utility.

Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.

Use this link to contact us and schedule a meeting.

View Event →
AACC Annual Scientific Meeting &amp; Clinical Lab Expo 2023
Jul
25
to 27 Jul

AACC Annual Scientific Meeting & Clinical Lab Expo 2023

The APIS team will be exhibiting at AACC Annual Scientific Meeting & Clinical Lab Expo 2023. 

Be sure not to miss our team of experts at Booth 2482.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.

Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.

The APIS Breast Cancer Subtyping Kit (RUO) is a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.

The new APIS ESR1 Mutations Kit is a research use only, advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

Use this link to contact us and schedule a meeting.


View Event →
Liverpool Pathology 2023
Jun
27
to 29 Jun

Liverpool Pathology 2023

Join the APIS Team at Liverpool Pathology 2023 for the 14th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society.

27-29th June 2023

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.

APIS has deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.

The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

The new APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

Interested in learning more? Use this link to contact us and schedule a meeting.

View Event →
Antibody Engineering & Therapeutics Europe
Jun
6
to 8 Jun

Antibody Engineering & Therapeutics Europe

The APIS team will be exhibiting and speaking at the Antibody Engineering & Therapeutics Europe conference at the Postillion Hotel, Amsterdam.

Come and meet us at stand 21.

APIS’ deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as diagnostic tests.

Innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.

The APIS SARS-CoV-2 IgG ELONA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum and utilises Clickmers. The results of this assay will aid in clinical decision making, vaccine development and booster dosing, and clinical research studies.

Interested in learning more? Use this link to contact us and schedule a meeting.

View Event →
Clickmers Webinar
May
9

Clickmers Webinar

Join Dr. Maren Hamann and Dr. Nora Karnowski for a must-attend virtual webinar that will introduce the revolutionary Clickmer Systems.

Synthetic affinity reagents known as Clickmers are chemically modified ssDNA oligonucleotides that, based on their sequence and modifications, form three-dimensional structures that adaptively bind to their target molecules with high affinity and specificity.

Clickmers can be used, for example, to detect viral infections, determine vaccination status or detect rejection reactions after organ transplants.

We hope you can join us on:

Tue 9th May, 14:00 PM - 15:00 PM (GMT)

To register follow the link: https://bit.ly/3AhWvwh

View Event →
13th Clinical Biomarkers & CDx Europe 2023
Apr
26
to 27 Apr

13th Clinical Biomarkers & CDx Europe 2023

The APIS Team will be exhibiting and presenting at the 13th Clinical Biomarkers & CDx Europe 2023 in London.

Be sure not to miss our Chief Operating Officer, Ian Kavanagh, presenting on Day 1 at 9:50 AM in the plenary session with his talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.

  • Discovering the potential of the APIS Breast Cancer Subtyping Kit for faster HER2 result turnaround without the need for reflex testing to ISH

  • Learning how to significantly reduce time for results interpretation with automatic results via validated software

  • The detection ability of lowly expressed ERBB2 levels aligns the IVD test as a CDx to HER2 targeted therapies, such as Trastuzumab deruxtecan

Interested in learning more? Use this link to contact us and schedule a meeting.

View Event →
ECCMID 2023
Apr
15
to 18 Apr

ECCMID 2023

The APIS Team will be exhibiting at ECCMID 2023 in Copenhagen, Denmark.

APIS Assay Technologies core expertise and capabilities are contract development of molecular & immunoassay assays and their ultimate product realisation as IVD approved assays, and the related clinical compliance services (particularly for CE-IVDR).

Operating under ISO 13485 and supported by the required clinical & compliance teams, we have expertise in developing PCR (RT-qPCR, qPCR, dPCR), NGS and immunoassay (e.g. ELISA & ELONA) IVD tests. Our onsite microbiology facilities provide our clients the capabilities to develop multiplex infectious disease panels in-house.

Our new APIS SARS-CoV-2 IgG ELISA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum. The assays’ results will aid in clinical decision making, vaccine development and booster dosing, disease prevention and research studies.

Interested in learning more? Use this link to contact us and schedule a meeting.

View Event →